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low BMD at, at least one of the sites considered. At the
recommended cutoff point of 6, SCORE had a sensitivity
of 91.5% to detect a low BMD at any site, a specificity of
26.5%, a positive predictive value of 52.8% and a nega-
tive predictive value of 77.7%. For the hip the associated
indicators of SCORE ability to identify low BMD reached
respectively 97.4%, 21.1%; 20.1% and 97.5%. For the
femoral neck the parameters yielded were respectively
95.9%, 23.8%, 34.4% and 93.4%. At the lumbar spine
SCORE performed less well. Area under the Receiver
Operating Characteristic curve to detect low BMD at the
total hip and the femoral neck were 0.760 and 0.738 re-
spectively. CONCLUSIONS: In view of these results we
can conclude that, notwithstanding the high values of
sensitivity achieved (which are even higher in our experi-
ence than those reported in the princeps paper), SCORE
specificity is too low to be used as a diagnostic tool for
screening patients at high risk to later develop osteo-
porosis.
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Osteoporosis is a public health problem that not only ex-
erts significant morbidity and mortality to society but
also a heavy financial burden. An effective strategy for
controlling this disease is identifying high-risk population
for early intervention. OBJECTIVES: The purpose of this
study was to determine the age group most cost-effective
to screen for osteoporosis in elderly women. METH-
ODS: The study population is women from 50 to 79
years old, who have not incurred a bone fracture. All
costs and life-years saved from intervention were calcu-
lated using the 5-year backward induction, incorporating
the DEALE method. The analysis is done from the per-
spective of society and a 3% discount rate is used. The
variables in the analysis were extracted from the litera-
ture. RESULTS: The cost to save one life-year from
screening for osteoporosis ranges from $97,208 to
$180,533. The variable most sensitive in the model is the
cost of an annual bone scan; a 20% variation in price of
a bone scan shifts the cost-effectiveness ratio by 19 to
22%. If a bone scan is required every 5 years, this inter-
vention would be cost-effective for women 65 to 79 years
old, assuming an intervention is cost-effective if it costs
$50,000 or less per life-year saved. CONCLUSIONS:
The results in this model demonstrate that screening for
osteoporosis in the elderly female population is not cost-
effective between 50 to 79 years. Future research may in-
clude following a cohort of women in this age range and
assess all cost related to providing osteoporosis care for a
more complete account of total costs to society.
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OBJECTIVE: To evaluate age-specific prevalence rates
for pharmacological treatment and prevention of os-
teoporosis among commercially insured women 18 years
or older in a managed care environment. METHODS:
Administrative pharmacy claims data from four health
plans between July 1, 1997 and June 30, 1998 were used
to determine the number of women who received at least
one prescription for therapy indicated for the treatment
or prevention of osteoporosis. Therapies indicated for the
treatment of osteoporosis included alendronate 10 mg
and intranasal calcitonin. Therapies indicated for the pre-
vention of osteoporosis included alendronate 5 mg and
raloxifene. Use of hormone replacement therapy (HRT)
was also included as possible osteoporosis prevention
therapy. Study subjects must have been continuously en-
rolled for 12 months both prior to and following their
study enrollment date. RESULTS: Over 15% of the study
population (N  84,587 members) received osteoporosis
therapy. The prevalence of osteoporosis treatment with
alendronate 10 mg or intranasal calcitonin was 0.5%.
The prevalence of osteoporosis prevention with alen-
dronate 5 mg, raloxifene, or HRT was 15.2%. Os-
teoporosis therapy was most prevalent among women
aged 50 to 59. As age increased beyond 59 years, the use
of HRT tapered off while the use of alendronate, ralox-
ifene, and intranasal calcitonin increased. Of those who
received osteoporosis therapy, 96% received HRT, 2.1%
received alendronate 10 mg, 0.9% received intranasal
calcitonin, 0.6% received raloxifene, and 0.4% received
alendronate 5 mg. CONCLUSION: Although rates of
therapy in the four health plans echo national estimates,
the number of women receiving osteoporosis prevention
therapy remains low in comparison to the number of
women at risk for the disease.
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Generic measures of health status provide an important
common denominator for comparing the burden of ill-
ness across diseases. OBJECTIVES: To document illness
burden of early rheumatoid arthritis (RA) on health re-
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lated quality of life (HQL). METHODS: The SF-36
Health Survey (SF-36) was self-administered by 632 par-
ticipants of a double-blinded, randomized controlled
clinical trial of three treatments for RA. The burden of
early RA (3 years) on HQL was estimated by compar-
ing SF-36 scale scores with general US population norms
and benchmarks for 6 chronic conditions: diabetes, de-
pression, congestive heart failure (CHF), asthma, chronic
obstructive pulmonary disease (COPD) and osteoarthritis
(OA). General US population norms and disease specific
benchmarks were adjusted to the age, gender and race of
the early RA patients. RESULTS: SF-36 scale scores were
significantly (P  0.0001) lower for early RA patients,
relative to age, gender and race adjusted general US pop-
ulation norms. Scales measuring physical health status
were most affected by early RA compared to scales mea-
suring mental health status. Scale scores of early RA pa-
tients were as low or lower than those observed for pa-
tients with CHF, diabetes, OA, COPD, and asthma.
Early RA scores on mental health were better than those
observed for patients with depression. CONCLUSIONS:
HQL measures are helpful in quantifying the impact of
early RA on patient functioning and well being. Early RA
patients report substantially diminished functioning and
well being, compared to the general US population. Pa-
tients with early RA reported health status and function-
ing at least as low as patients commonly considered to
have more debilitating diseases.
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Non-steroid anti-inflammatory drugs (NSAID) are widely
used in Russia in all fields of medicine. At the same time
they produce serious side effects such as gastric or duode-
nal ulcer and gastrointestinal bleeding, that may influ-
ence the cost of illness. OBJECTIVE: The study purpose
was to conduct an economic analysis of two drug regi-
mens for rheumatoid arthritis and osteoarthritis: regimen
A (meloxicam 7.5 mg/day) regimen B (diclofenac 100
mg/day). METHODS: Decision-analysis was performed.
Clinical efficacy and probability of side effects was taken
from multicenter clinical trials. Costs of baseline treat-
ment and cost of treatment for side effects were analyzed.
RESULTS: Clinical efficacy in both regimens was equal.
Probability of side effects was 1.5 times higher in di-
clofenac than meloxicam (0.031 vs 0.019) according to
the trials. Cost of standard treatment for side effects was
$6.80 US for minor symptoms, $12.20 US for ulcer at
out-patient department, and $188.04 US for ulcer at hos-
pital. Such low costs are explained with low levels of
prices for medical services in the system of medical insur-
ance. Cost of period of treatment including treatment for
side effects was $20.09 US for diclofenac and $15.42 US
for meloxicam. CONCLUSIONS: Treatment with meloxi-
cam was cheaper than with diclofenac, but the difference
was mostly explained by the price of drugs, because
prices for medical services are very low in Russia. Pres-
ently in this country drug prices are most important, as
they are determined by market forces while prices for
medical services are regulated by the state and are low
because of limited resources.
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The introduction of celecoxib has led to the assumption that
utilization of antiulcerants may be reduced. OBJECTIVE:
The purpose of this clinical practice study was to assess
the cost benefit of switching arthritis patients from non-
steroidal anti-inflammatory drugs (NSAIDs) and con-
comitant antiulcerants to celecoxib. METHODS: 190 male
and female (67%) patients with osteoarthritis (157) or
rheumatoid arthritis (33) who were either maintained on an
NSAID or who could not tolerate prescription NSAIDs at
the baseline visit, were evaluated in this prospective, open-
label, nonrandomized study. Patients were switched or
started on celecoxib and counseled by the prescribing
physician to discontinue any antiulcerants and limit use
of OTC NSAIDs. Patients returned for 2 monthly follow-
up visits for further assessments and tabulation of con-
comitant drug use. RESULTS: Of the 110 patients
treated with traditional NSAIDs and/or disease modify-
ing agents, 25% were maintained on ibuprofen, 19% on
aspirin, and 13% were maintained on nabumetone or
diclofenacmisoprostol. 82 patients were taking a pro-
ton pump inhibitor (omeprazole [30] or lansoprazole
[14]), histamine antagonist (ranitidine [12] or famotidine
[11]), or misoprostol (9). Over a 3 month follow-up period,
71 (87%) of these patients had discontinued the antiul-
cerants at time of switching to celecoxib. Based upon AWP
pricing, the switch to celecoxib with discontinuation in
antiulcerants resulted in an average daily savings of $2.65
US per patient. CONCLUSION: Appropriate switching of
arthritic patients from their traditional NSAID and anti-
ulcerant to celecoxib results in a significant cost savings
to the patient and managed care organization.
